NervGen Pharma Corp.

Other · Canada

Last price 1.37 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 147.31M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company’s lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer’s disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Co...